Replies to post #129448 on Biotech Values

[NP1986]

Could we possibly see a fixed-dose formulation?

How is Complera doing?

[DewDiligence]

BMY, Teva settle Reyataz patent suit:

http://online.wsj.com/article/SB10001424052970203554104577001490166083700.html

As a result of the settlement, generic Reyataz will not hit the US market until 2017.

NVS, the licensor to BMY of one of the Reyataz patents at issue in this case, also settled with Teva.